Incyte

Incyte Corporation stands as a leading global biopharmaceutical innovator with headquarters in Wilmington, Delaware, dedicated to transforming patient care through groundbreaking medicines. Since its founding in 1991, the company has established itself as a pioneer in developing first-in-class therapies, particularly in the JAK inhibitor space, which has revolutionized treatment paradigms across oncology, hematology, inflammation, and autoimmunity.

The company's flagship product, Jakafi (ruxolitinib), approved in 2011, marked a watershed moment in rare blood cancer treatment and has since expanded to treat polycythemia vera, myelofibrosis, and graft-versus-host disease. This breakthrough established Incyte's reputation for scientific excellence and commercial execution. The company has since built a robust commercial portfolio including Opzelura, the first topical JAK inhibitor approved for atopic dermatitis and vitiligo, which generated $508 million in revenue in 2024 with 50% year-over-year growth. Additional marketed products include Iclusig for chronic myeloid leukemia, Pemazyre for cholangiocarcinoma, Tabrecta for lung cancer, and Monjuvi for diffuse large B-cell lymphoma.

Incyte's financial performance reflects strong commercial momentum, with total revenue reaching $4.24 billion in 2024, representing 14.76% growth year-over-year. Jakafi remains the cornerstone, generating $2.8 billion annually, while the expanding portfolio and deep pipeline drive future growth. The company employs over 2,600 professionals globally, including more than 1,000 world-class scientists, operating manufacturing and R&D facilities across North America, Europe, and Asia.

Under new leadership with Bill Meury as CEO (appointed June 2025, succeeding 11-year veteran Hervé Hoppenot), Incyte is positioned for its next phase of growth. The company expects four new product launches in 2025, including Niktimvo for chronic graft-versus-host disease, pediatric formulations of ruxolitinib cream, tafasitamab for follicular lymphoma, and retifanlimab for anal carcinoma. The robust pipeline includes late-stage programs in BET inhibitors for myelofibrosis, novel oncology therapies, and dermatology innovations, supported by strategic acquisitions like Escient Pharmaceuticals ($750 million, 2024) and Villaris Therapeutics ($1.4 billion, 2022).

Incyte's commitment to patients extends beyond drug development to creating an award-winning workplace culture. For the seventh consecutive year, Science Magazine named Incyte a top-five biotech and pharma employer in 2024. The company ranked among Newsweek's Global Top 100 Most Loved Workplaces and received a 5-star rating for diversity. This culture, rooted in the "Solve On" mission and values of integrity and patient focus, attracts top talent and drives innovation that advances quality of life for patients worldwide. With a market capitalization of approximately $13.3 billion and a strategic focus on high-value therapeutic areas, Incyte continues to establish itself as a formidable force in global biopharmaceuticals.